165 related articles for article (PubMed ID: 33108240)
1. An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Chatzopoulos G; Tziomalos K
Expert Opin Pharmacother; 2020 Oct; 21(15):1799-1803. PubMed ID: 33108240
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sotagliflozin in treating diabetes type 1.
Rendell MS
Expert Opin Pharmacother; 2018 Feb; 19(3):307-315. PubMed ID: 29212386
[TBL] [Abstract][Full Text] [Related]
3. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Garg SK; Henry RR; Banks P; Buse JB; Davies MJ; Fulcher GR; Pozzilli P; Gesty-Palmer D; Lapuerta P; Simó R; Danne T; McGuire DK; Kushner JA; Peters A; Strumph P
N Engl J Med; 2017 Dec; 377(24):2337-2348. PubMed ID: 28899222
[TBL] [Abstract][Full Text] [Related]
4. Sotagliflozin: A Review in Type 1 Diabetes.
Deeks ED
Drugs; 2019 Dec; 79(18):1977-1987. PubMed ID: 31761990
[TBL] [Abstract][Full Text] [Related]
5. Sotagliflozin: First Global Approval.
Markham A; Keam SJ
Drugs; 2019 Jun; 79(9):1023-1029. PubMed ID: 31172412
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Musso G; Gambino R; Cassader M; Paschetta E
BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
8. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
9. HbA
Danne T; Cariou B; Banks P; Brandle M; Brath H; Franek E; Kushner JA; Lapuerta P; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1981-1990. PubMed ID: 29937431
[TBL] [Abstract][Full Text] [Related]
10. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
11. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Cariou B; Charbonnel B
Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
[TBL] [Abstract][Full Text] [Related]
12. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
13. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
[No Abstract] [Full Text] [Related]
14. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
[TBL] [Abstract][Full Text] [Related]
15. Sodium/glucose cotransporter 2 inhibitors for the treatment of type 1 diabetes: what are the latest developments?
Veneti S; Tziomalos K
Expert Opin Pharmacother; 2021 Nov; 22(16):2261-2266. PubMed ID: 34402702
[TBL] [Abstract][Full Text] [Related]
16. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Peters AL; McGuire DK; Danne T; Kushner JA; Rodbard HW; Dhatariya K; Sawhney S; Banks P; Jiang W; Davies MJ; Lapuerta P
Diabetes Care; 2020 Nov; 43(11):2713-2720. PubMed ID: 32928957
[TBL] [Abstract][Full Text] [Related]
17. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
[TBL] [Abstract][Full Text] [Related]
18. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
Buse JB; Garg SK; Rosenstock J; Bailey TS; Banks P; Bode BW; Danne T; Kushner JA; Lane WS; Lapuerta P; McGuire DK; Peters AL; Reed J; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1970-1980. PubMed ID: 29937430
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
[TBL] [Abstract][Full Text] [Related]
20. The journey from gene knockout to clinical medicine: telotristat and sotagliflozin.
Rendell MS
Drug Des Devel Ther; 2019; 13():817-824. PubMed ID: 30880915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
